These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35122023)

  • 21. The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.
    Abdel-Wahab O; Dey A
    Leukemia; 2013 Jan; 27(1):10-5. PubMed ID: 23147254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deregulation of tumor suppressive ASXL1-PTEN/AKT axis in myeloid malignancies.
    Cao L; Xia X; Kong Y; Jia F; Yuan B; Li R; Li Q; Wang Y; Cui M; Dai Z; Zheng H; Christensen J; Zhou Y; Wu X
    J Mol Cell Biol; 2020 Sep; 12(9):688-699. PubMed ID: 32236560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural basis of histone H2A lysine 119 deubiquitination by Polycomb Repressive Deubiquitinase BAP1/ASXL1.
    Thomas JF; Valencia-Sánchez MI; Tamburri S; Gloor SL; Rustichelli S; Godínez-López V; De Ioannes P; Lee R; Abini-Agbomson S; Gretarsson K; Burg JM; Hickman AR; Sun L; Gopinath S; Taylor H; Meiners MJ; Cheek MA; Rice W; Nudler E; Lu C; Keogh MC; Pasini D; Armache KJ
    bioRxiv; 2023 Feb; ():. PubMed ID: 36865140
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncogenic Truncations of ASXL1 Enhance a Motif for BRD4 ET-Domain Binding.
    Burgess AE; Kleffmann T; Mace PD
    J Mol Biol; 2021 Nov; 433(22):167242. PubMed ID: 34536441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals.
    Wu X; Bekker-Jensen IH; Christensen J; Rasmussen KD; Sidoli S; Qi Y; Kong Y; Wang X; Cui Y; Xiao Z; Xu G; Williams K; Rappsilber J; Sønderby CK; Winther O; Jensen ON; Helin K
    Cell Res; 2015 Nov; 25(11):1205-18. PubMed ID: 26470845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.
    Yang H; Kurtenbach S; Guo Y; Lohse I; Durante MA; Li J; Li Z; Al-Ali H; Li L; Chen Z; Field MG; Zhang P; Chen S; Yamamoto S; Li Z; Zhou Y; Nimer SD; Harbour JW; Wahlestedt C; Xu M; Yang FC
    Blood; 2018 Jan; 131(3):328-341. PubMed ID: 29113963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo.
    Guo Y; Yang H; Chen S; Zhang P; Li R; Nimer SD; Harbour JW; Xu M; Yang FC
    Leukemia; 2018 Aug; 32(8):1834-1837. PubMed ID: 29743720
    [No Abstract]   [Full Text] [Related]  

  • 28. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
    Abdel-Wahab O; Adli M; LaFave LM; Gao J; Hricik T; Shih AH; Pandey S; Patel JP; Chung YR; Koche R; Perna F; Zhao X; Taylor JE; Park CY; Carroll M; Melnick A; Nimer SD; Jaffe JD; Aifantis I; Bernstein BE; Levine RL
    Cancer Cell; 2012 Aug; 22(2):180-93. PubMed ID: 22897849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BAP1/ASXL complex modulation regulates epithelial-mesenchymal transition during trophoblast differentiation and invasion.
    Perez-Garcia V; Lea G; Lopez-Jimenez P; Okkenhaug H; Burton GJ; Moffett A; Turco MY; Hemberger M
    Elife; 2021 Jun; 10():. PubMed ID: 34170818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ASXLs binding to the PHD2/3 fingers of MLL4 provides a mechanism for the recruitment of BAP1 to active enhancers.
    Zhang Y; Xie G; Lee JE; Zandian M; Sudarshan D; Estavoyer B; Benz C; Viita T; Asgaritarghi G; Lachance C; Messmer C; Simonetti L; Sinha VK; Lambert JP; Chen YW; Wang SP; Ivarsson Y; Affar EB; Côté J; Ge K; Kutateladze TG
    Nat Commun; 2024 Jun; 15(1):4883. PubMed ID: 38849395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.
    Zhang P; He F; Bai J; Yamamoto S; Chen S; Zhang L; Sheng M; Zhang L; Guo Y; Man N; Yang H; Wang S; Cheng T; Nimer SD; Zhou Y; Xu M; Wang QF; Yang FC
    J Clin Invest; 2018 Dec; 128(12):5383-5398. PubMed ID: 30226831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers.
    Kuznetsov JN; Aguero TH; Owens DA; Kurtenbach S; Field MG; Durante MA; Rodriguez DA; King ML; Harbour JW
    Sci Adv; 2019 Sep; 5(9):eaax1738. PubMed ID: 31555735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rare germline heterozygous missense variants in BRCA1-associated protein 1, BAP1, cause a syndromic neurodevelopmental disorder.
    Küry S; Ebstein F; Mollé A; Besnard T; Lee MK; Vignard V; Hery T; Nizon M; Mancini GMS; Giltay JC; Cogné B; McWalter K; Deb W; Mor-Shaked H; Li H; Schnur RE; Wentzensen IM; Denommé-Pichon AS; Fourgeux C; Verheijen FW; Faurie E; Schot R; Stevens CA; Smits DJ; Barr E; Sheffer R; Bernstein JA; Stimach CL; Kovitch E; Shashi V; Schoch K; Smith W; van Jaarsveld RH; Hurst ACE; Smith K; Baugh EH; Bohm SG; Vyhnálková E; Ryba L; Delnatte C; Neira J; Bonneau D; Toutain A; Rosenfeld JA; ; Audebert-Bellanger S; Gilbert-Dussardier B; Odent S; Laumonnier F; Berger SI; Smith ACM; Bourdeaut F; Stern MH; Redon R; Krüger E; Margueron R; Bézieau S; Poschmann J; Isidor B
    Am J Hum Genet; 2022 Feb; 109(2):361-372. PubMed ID: 35051358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of ASXL1 in hematopoiesis and myeloid malignancies.
    Asada S; Fujino T; Goyama S; Kitamura T
    Cell Mol Life Sci; 2019 Jul; 76(13):2511-2523. PubMed ID: 30927018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1.
    Daou S; Barbour H; Ahmed O; Masclef L; Baril C; Sen Nkwe N; Tchelougou D; Uriarte M; Bonneil E; Ceccarelli D; Mashtalir N; Tanji M; Masson JY; Thibault P; Sicheri F; Yang H; Carbone M; Therrien M; Affar EB
    Nat Commun; 2018 Oct; 9(1):4385. PubMed ID: 30349006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural Basis for the Activation of the Deubiquitinase Calypso by the Polycomb Protein ASX.
    De I; Chittock EC; Grötsch H; Miller TCR; McCarthy AA; Müller CW
    Structure; 2019 Mar; 27(3):528-536.e4. PubMed ID: 30639226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
    Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
    Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.
    Bott M; Brevet M; Taylor BS; Shimizu S; Ito T; Wang L; Creaney J; Lake RA; Zakowski MF; Reva B; Sander C; Delsite R; Powell S; Zhou Q; Shen R; Olshen A; Rusch V; Ladanyi M
    Nat Genet; 2011 Jun; 43(7):668-72. PubMed ID: 21642991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
    Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
    Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
    Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
    J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.